[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354203-105":59,"doc-detail-354203-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinicopathologic-characteristics-and-genomic-profiling-of-her2-low-advanced-gastric-or-gastroesophageal-junction-cancer","Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer","","Human epidermal growth factor 2 (HER2)-low expression has emerged as a potential therapeutic target enabled by HER2-directed antibody–drug conjugates, yet clinicopathologic and molecular characteristics in advanced gastric or gastroesophageal junction (G/GEJ) cancer remain insufficiently defined. A retrospective analysis of 2007 stage IV cases (2015–2022) evaluated HER2-high, HER2-low, and HER2-null subgroups, integrating survival and first-line treatment including immune checkpoint inhibitors. Molecular profiling of 777 tumors used in-house next-generation sequencing to define pathway alterations in HER2-low.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinicopathologic-characteristics-and-genomic-profiling-of-her2-low-advanced-gastric-or-gastroesophageal-junction-cancer/354203/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinicopathologic-characteristics-and-genomic-profiling-of-her2-low-advanced-gastric-or-gastroesophageal-junction-cancer/354203.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were HER2 statuses classified in this study of advanced G/GEJ cancer?","Question",{"text":112,"@type":113},"HER2-high was defined as IHC 3+ or IHC 2+/ISH+, HER2-low as IHC 2+/ISH− or IHC 1+, and HER2-null as IHC 0.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What clinicopathologic and survival patterns were observed for HER2-low compared with HER2-null tumors?",{"text":117,"@type":113},"HER2-low tumors closely resembled HER2-null tumors in histopathology, EBV status, MSI, and PD-L1 status. In the survival cohort, HER2-low showed intermediate progression-free survival and overall survival, and ICIs provided greater benefit in HER2-low than in HER2-null.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular features distinguished HER2-low tumors in next-generation sequencing analyses?",{"text":121,"@type":113},"In the NGS cohort, HER2-low tumors were significantly enriched for angiogenesis pathway alterations, which were linked to worse survival and were not seen in other HER2 subgroups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354203,1790151399,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ORIGINAL ARTICLE  \nClinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer  \nC. K. Lee1 , 2‡, D. H. Seo2 , 3‡, S. Park2, T. Yuh3, Y. Kim3, H. Park3, J. S. Shim3, H. Kim4, H. S. Kim1 , 2, M. Jung1 , 2, H. C. Chung1 , 2 &  \nS. Y. Rha1 , 2 , 5 ∗  \n1Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center; 2Song-Dang Institute for Cancer Research; 3Departments of Internal Medicine; 4Pathology; 5Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea  \nAvailable online xxx  \nBackground: Human epidermal growth factor 2 (HER2)-low expression has recently emerged as a potential therapeutic target with the advent of HER2-directed antibody—drug conjugates. However, the clinicopathologic and molecular features of HER2-low advanced gastric or gastroesophageal junction (G/GEJ) cancer remain inadequately characterized.  \nPatients and methods: We retrospectively analyzed 2007 patients with stage IV G/GEJ cancer treated between 2015 and 2022 at Yonsei Cancer Center, Korea. HER2 status was classified as HER2-high (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), HER2-low (IHC 2+/ISH − or IHC 1+) and HER2-null (IHC 0) . Clinicopathologic features and survival outcomes were assessed in patients receiving first-line doublet chemotherapy with or without immune checkpoint inhibitors (ICIs) . For molecular analyses, pretreatment tumors from 777 patients underwent in-house next-generation sequencing (NGS), excluding Epstein—Barr virus (EBV)—positive and microsatellite instability (MSI)—high cases.  \nResults: Among 2007 patients, 372 (18 .5%) were HER2-high, 523 (26 . 1%) were HER2-low, and 1112 (55 .4%) were HER2-null. HER2-low tumors closely resembled HER2-null tumors in histopathology, EBV status, MSI, and programmed death-ligand 1 status. In the survival analysis cohort (n = 1417), first-line progression-free survival was 8.0 months (HER2-high), 6.0 months (HER2-low), and 6.1 months (HER2-null), while overall survival was 17. 2, 13.4, and 14.5 months, respectively. Combination with ICIs conferred greater survival benefit in HER2-low tumors compared with HER2-null tumors. In the NGS cohort (n = 777), HER2-low tumors were significantly enriched for angiogenesis pathway alterations, which were associated with worse survival, a pattern not observed in other subgroups.  \nConclusions: HER2-low G/GEJ cancer represents a distinct biological subtype with intermediate survival outcomes and specific angiogenesis-related molecular features. These findings support the need for dedicated therapeutic strategies and further clinical research in HER2-low G/GEJ cancer.  \nKey words: HER2-low, gastric cancer, gastroesophageal junction cancer, immunotherapy, molecular profiling  \nINTRODUCTION  \nGastric and gastroesophageal junction (G/GEJ) cancer is the second leading cause of cancer-related deaths and the fifth most common cancer worldwide, and Eastern Asia has oneof the highest incidence rates.1 Doublet chemotherapy with  \n*Correspondence to: Prof. Sun Young Rha, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; or Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea. Tel: +82- 2-2228-8053  \n[E-mail:](E-mail: RHA7655@yuhs.ac)[ RHA7655@yuhs.ac](E-mail: RHA7655@yuhs.ac) (S. Y. Rha).  \n‡Both authors contributed equally to this work.  \n2059-7029/© 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nplatinum and fluoropyrimidines, with or without immune checkpoint inhibitors (ICIs), is the recommended palliative first-line therapy for patients with advanced G/GEJ","cbCaivMHR35VmyY7","https://ap.wps.com/l/cbCaivMHR35VmyY7","pdf",4400458,"English","# Background\n# Patients and methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"How were HER2 statuses classified in this study of advanced G/GEJ cancer?\",\"answer\":\"HER2-high was defined as IHC 3+ or IHC 2+/ISH+, HER2-low as IHC 2+/ISH− or IHC 1+, and HER2-null as IHC 0.\"},{\"question\":\"What clinicopathologic and survival patterns were observed for HER2-low compared with HER2-null tumors?\",\"answer\":\"HER2-low tumors closely resembled HER2-null tumors in histopathology, EBV status, MSI, and PD-L1 status. In the survival cohort, HER2-low showed intermediate progression-free survival and overall survival, and ICIs provided greater benefit in HER2-low than in HER2-null.\"},{\"question\":\"What molecular features distinguished HER2-low tumors in next-generation sequencing analyses?\",\"answer\":\"In the NGS cohort, HER2-low tumors were significantly enriched for angiogenesis pathway alterations, which were linked to worse survival and were not seen in other HER2 subgroups.\"}]","Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer | PDF",1790109447,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b47fd945d5c652af2a5ea210ef089de.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd64211e5d9c5c55a6a5747dccf18e08.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b23861b18dc0ac371c8a39444a0d8dc9.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/806358e4eb1fb35661ad0c3c04e6c486.webp",980,1265]